Edgewise Therapeutics has reported phase 2 data on its cardiomyopathy prospect, keeping the biotech on track to start pivotal development of a would-be challenger to Bristol Myers Squibb and Cytokinetics. fiercebiotech.com/biotech/ed…

Clear tell of underperforming teams: use the gerund a lot. Transforming Planning Is building We are talking We are putting

Amgen’s up-to-$2.5 billion acquisition of the antibody specialist Teneobio is costing the California drugmaker once again. fiercebiotech.com/biotech/am…

‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO fiercepharma.com/pharma/if-t…

Eli Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate,’ while putting Incyte on notice #EHA26 fiercebiotech.com/biotech/li…

excellent balanced piece by @FierceBiotech on $celc results. i purchased more on this dip ($6b fdmc w/ a $3b initial pys estimate for just the first two indications in 2l). fiercebiotech.com/biotech/as…

Despite challenging macro conditions, the biotech market has seen two record-setting IPOs in three months. @BDO_USA's Brad Stewart spoke with @FierceBiotech to explore the full picture behind the IPO momentum. Learn more: bdousa.com/447Sgm0

Despite challenging macro conditions, the biotech market has seen two record-setting IPOs in three months. @BDO_USA's Brad Stewart spoke with @FierceBiotech to explore the full picture behind the IPO momentum. Learn more: bdousa.com/4onhwxU

Despite challenging macro conditions, the biotech market has seen two record-setting IPOs in three months. @BDO_USA's Brad Stewart spoke with @FierceBiotech to explore the full picture behind the IPO momentum. Learn more: bdousa.com/4v6JiRM

Despite challenging macro conditions, the biotech market has seen two record-setting IPOs in three months. Our Brad Stewart spoke with @FierceBiotech to explore the full picture behind the IPO momentum. Learn more: bdousa.com/4vDv9eW

#AI isn't just supporting #clinicaldevelopment anymore — it's becoming the infrastructure for how sponsors make decisions. ⚖️ In this interview, Aaron Smith explains how #digitaltwin models connected to patient data and published literature are reshaping trial planning, monitoring, and analysis. He walks through a recent case where historical data from published papers feeds directly into sample size calculations. How AI flags quality issues without unblinding the #trial. Why regulators are pushing back on synthetic-only controls but greenlighting hybrid approaches. If you're navigating #AIcredibility with regulators or wondering what's actually viable in clinical development right now, watch the full interview. na2.hubs.ly/H065qqC0 ——— @FierceBiotech

Chutes & Ladders—Perrigo CEO ousted over ‘personal conduct’ fiercebiotech.com/biotech/ch…

Today on The Top Line, Fierce EIC @AylaEllison sits down with Ipsen's R&D chief to discuss the biopharma's approach to partnerships, its strategy for expanding the pipeline, and where its focus is in 2026. fiercebiotech.com/biotech/ip…

Join @ChemPartner for a New @FierceBiotech Webinar July 23rd: “Conjugation Strategies Across Emerging Therapeutic Modalities” where Dr. Philip Clarke, PhD, will highlight advances in next‑generation conjugation. #Chemistry 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄👉 fiercebiotech.com/premium/we…

Three Genentech VPs are among those dismissed in another round of layoffs by the Roche subsidiary. fiercebiotech.com/biotech/ge…

Caribou Biosciences has linked its CAR-T cell therapy candidate to 17.1-month median progression-free survival, adding to evidence that the off-the-shelf treatment can match the efficacy of autologous products in lymphoma patients. fiercebiotech.com/biotech/ca…

Parabilis Medicines’ IPO has lived up to the hype—securing $670 million for the largest listing in the biotech sector’s history. fiercebiotech.com/biotech/ca…